Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
Key facts
- Who runs it
- Vaxcyte, Inc.
- Where
- Austin, Beaumont, Charlottesville, Chinle, Edmond, Gallup, Hendersonville, Hollywood, Jupiter, Kansas City, Lenexa, New Orleans, Newport News, Omaha, Phoenix, Port Saint Lucie, Rochester, Rockville, San Antonio, Shiprock, Southfield, Springfield, Stockbridge, Sugar Land, Sunrise, The Villages, Valparaiso, Waterbury, Whiteriver, and Wilmington, United StatesSee the 30 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 752 people enrolled
- Started
- 9 Feb 2026
- Ended
- 25 Oct 2026
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 31-valent pneumococcal conjugate vaccine
- PCV20
- Record updated
- 13 November 2026
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 24 criteriaShow less
Who can take part
- Male or female ≥50 years of age (inclusive) at the time of randomization into the study
- Previous receipt of a licensed pneumococcal vaccine or combination of licensed vaccines, with most recent vaccination ≥1 year prior to randomization; the exception is PCV21, which may have been received ≥6 months prior to randomization (confirmed)
- Able and willing to complete the informed consent process
- Available for clinical follow-up through the last study visit
- In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator)
- Willing to have blood samples collected and used for research purposes
- Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process
- Female participants of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method
- Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary)
Who cannot take part
- Previous receipt of an investigational pneumococcal vaccine at any age
- Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study
- Receipt of any live vaccine within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1
- Body temperature >38.0°C (>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened)
- History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination
- Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study
- Is currently receiving immunosuppressive or immune-modifying therapy, including systemic corticosteroids (this includes ≥3 months of prednisone equivalent from 5 to ≤10 mg/day and ≥2 weeks of prednisone equivalent >10 mg/day)
- Current diagnosis of human immunodeficiency virus, Hepatitis B, or Hepatitis C
- Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency
- Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent
- Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws
- Previous invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age
- Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent >10 mg/day) within 14 days of study vaccination; History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation
- Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site
Where in United States
- Tekton ResearchAustin, United States
- REX Clinical TrialsBeaumont, United States
- Alcanza (Charlottesville Medical Research)Charlottesville, United States
- Chinle Center for Indigenous HealthChinle, United States
- Tekton ResearchEdmond, United States
- Center of American Indian HealthGallup, United States
- DelRicht ResearchHendersonville, United States
- CenExel RCAHollywood, United States
- Eximia (Health Awareness)Jupiter, United States
- AMRKansas City, United States
- Johnson County Clin-Trials, LLCLenexa, United States
- DelRicht Clinical ResearchNew Orleans, United States
- Health Research of Hampton Roads, Inc.Newport News, United States
- Quality Clinical ResearchOmaha, United States
- Avacare (CCT Research)Phoenix, United States
- Eximia (Health Awareness)Port Saint Lucie, United States
- Rochester Clinical Research, IncRochester, United States
- Velocity (Meridian Clinical Research)Rockville, United States
- Flourish ResearchSan Antonio, United States
- Shiprock Center for Indigenous HealthShiprock, United States
- DM Clinical Research - DetroitSouthfield, United States
- Delricht Research - Command Family MedicineSpringfield, United States
- DelRicht Clinical ResearchStockbridge, United States
- DM Clinical ResearchSugar Land, United States
- Precision Clinical ResearchSunrise, United States
- The VillagesThe Villages, United States
- Velocity Clinical_ValparaisoValparaiso, United States
- Chase Medical ResearchWaterbury, United States
- Whiteriver Center for Indigenous HealthWhiteriver, United States
- Headlands (Trial Management Associates)Wilmington, United States
About the trial
What the trial wants to find out
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
The 6 groups in the trial
- Cohort 1 (VAX-31): Prior PPSV23Treatment being tested
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Treatment: 31-valent pneumococcal conjugate vaccine
- Cohort 1 (PCV20): Prior PPSV23Existing treatment, for comparison
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Treatment: PCV20
- Cohort 2 (VAX-31): Prior PCV20Treatment being tested
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Treatment: 31-valent pneumococcal conjugate vaccine
- Cohort 2 (PCV20): Prior PCV20Existing treatment, for comparison
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Treatment: PCV20
- Cohort 3 (VAX-31): Other prior licensed pneumococcal vaccine or combinationTreatment being tested
Participants will receive a single dose of VAX-31 administered via intramuscular injection at Day 1
Treatment: 31-valent pneumococcal conjugate vaccine
- Cohort 3 (PCV20): Other prior licensed pneumococcal vaccine or combinationExisting treatment, for comparison
Participants will receive a single dose of PCV20 (Prevnar 20) administered via intramuscular injection at Day 1
Treatment: PCV20
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination
- Record updated
- 13 November 2026